Literature DB >> 19022822

How to cope with pathogenic long-lived plasma cells in autoimmune diseases.

B F Hoyer1, I M Mumtaz, T Yoshida, F Hiepe, A Radbruch.   

Abstract

Recently, it has been shown that plasma cells secreting antibodies can be long lived and as such constitute an independent component of immunological memory. They are generated in the context of memory immune reactions and migrate to the bone marrow, where they persist for years and decades. Their survival is dependent on receiving distinct signals provided by cells forming a plasma cell survival niche. They also can migrate to, and survive in, inflamed tissue. In autoimmune diseases long-lived plasma cells secreting autoantibodies provide an as yet unmet therapeutic challenge, because they are resistant to conventional treatments, in particular to immunosuppression and anti-inflammatory drugs. They are eliminated by immunoablation with antithymocyte globulin. This may be the reason why immunoablation followed by reconstitution of the patient's immune system from haematopoietic stem cells induces long-term remissions in many patients with autoimmune diseases. However, more specific treatments for the elimination of autoreactive, long-lived plasma cells are needed, to avoid the complete temporary immunoincomptence induced by immunoablation, and to decipher the role of long-lived autoreactive plasma cells in human autoimmune diseases in more detail.

Entities:  

Mesh:

Year:  2008        PMID: 19022822     DOI: 10.1136/ard.2008.098418

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  9 in total

1.  Stem cell transplantation for autoimmune diseases.

Authors:  Thomas Hügle; Thomas Daikeler
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

2.  Sockeye salmon retain immunoglobulin-secreting plasma cells throughout their spawning journey and post-spawning.

Authors:  Jonathan Schouten; Terri Clister; Amber Bruce; Lidia Epp; Patty Zwollo
Journal:  Dev Comp Immunol       Date:  2013-02-19       Impact factor: 3.636

Review 3.  [Immunomodulatory therapy of autoimmune diseases : Quo vadis?].

Authors:  B F Hoyer; F Hiepe
Journal:  Ophthalmologe       Date:  2016-05       Impact factor: 1.059

4.  Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.

Authors:  Alba Llop-Guevara; Mónica Porras; Carla Cendón; Irene Di Ceglie; Francesco Siracusa; Federica Madarena; Vagelis Rinotas; Lluís Gómez; Peter L van Lent; Eleni Douni; Hyun Dong Chang; Thomas Kamradt; Juan Román
Journal:  Arthritis Res Ther       Date:  2015-12-10       Impact factor: 5.156

5.  The chronically inflamed central nervous system provides niches for long-lived plasma cells.

Authors:  Karolin Pollok; Ronja Mothes; Carolin Ulbricht; Alina Liebheit; Jan David Gerken; Sylvia Uhlmann; Friedemann Paul; Raluca Niesner; Helena Radbruch; Anja Erika Hauser
Journal:  Acta Neuropathol Commun       Date:  2017-11-25       Impact factor: 7.801

6.  Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.

Authors:  Robert Wilson; Mateusz Makuch; Anne-Kathrin Kienzler; James Varley; Jennifer Taylor; Mark Woodhall; Jacqueline Palace; M Isabel Leite; Patrick Waters; Sarosh R Irani
Journal:  Brain       Date:  2018-04-01       Impact factor: 13.501

7.  TLR2, TLR4 and the MyD88 signaling are crucial for the in vivo generation and the longevity of long-lived antibody-secreting cells.

Authors:  Evilin Naname Komegae; Lidiane Zito Grund; Monica Lopes-Ferreira; Carla Lima
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

8.  Allergic sensitization: host-immune factors.

Authors:  Ronald van Ree; Lone Hummelshøj; Maud Plantinga; Lars K Poulsen; Emily Swindle
Journal:  Clin Transl Allergy       Date:  2014-04-15       Impact factor: 5.871

Review 9.  Human B cell memory.

Authors:  Antonio Lanzavecchia; Federica Sallusto
Journal:  Curr Opin Immunol       Date:  2009-06-06       Impact factor: 7.486

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.